Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 6 of 6 for “"wapps-hemo"”.

  1. A RANDOMIZED WAIT-LIST, PILOT DESIGN THESIS: Feasibility of the Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Tool in Severe Hemophilia Patients Undertaking Personalized Regimen Tailoring

    … running a full-scale RCT with the newly designed WAPPS-Hemo calculator in the Canadian Hemophilia community. The WAPPS-Hemo calculator is widely viewed as a beneficial tool to clinicians and patients and has the potential to optimize and tailor the prophylaxis regimen for hemophilia patients.

    mcmaster Repository record for A RANDOMIZED WAIT-LIST, PILOT DESIGN THESIS: Feasibility of the Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Tool in Severe Hemophilia Patients Undertaking Personalized Regimen Tailoring (opens in a new tab)

  2. The Usability Testing of the Web Accessible Population Pharmacokinetics Service- Hemophilia

    Hemophilia is a genetic disorder that is caused by deficiencies in coagulation factor VIII and factor IX. Optimal management of hemophilia requires tailoring the dose of treatment to the individual patient’s need. This tailoring is based on several clinical considerations, for example, bleeding …

    mcmaster Repository record for The Usability Testing of the Web Accessible Population Pharmacokinetics Service- Hemophilia (opens in a new tab)

  3. Clinical application of the Web-Accessible Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo): proposal for a pilot study of a population pharmacokinetic approach to tailored prophylaxis in hemophilia.

    … way to improve the global clinical benefit of hemophilia treatment could be adopting a tailored prophylaxis regimen. To execute a tailored prophylaxis treatment scheme is necessary the evaluation of pharmacokinetic (PK) parameters acquired after the infusion of clotting factor concentrates at …

    mcmaster Repository record for Clinical application of the Web-Accessible Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo): proposal for a pilot study of a population pharmacokinetic approach to tailored prophylaxis in hemophilia. (opens in a new tab)

  4. Pharmacokinetic modelling of clinically relevant situations in the treatment of hemophilia A and B

    Hemophilia is a congenital bleeding disorder caused by deficiency of clotting factor VIII (FVIII; hemophilia A) or IX (FIX; hemophilia B). Severe hemophilia patients have less than 1% (or 1 IU/dL) of normal factor activity, and often experience spontaneous bleeding episodes. This often occurs in …

    waterloo Repository record for Pharmacokinetic modelling of clinically relevant situations in the treatment of hemophilia A and B (opens in a new tab)

  5. Haemophilia A - In pursuit of optimised outcomes via personalised treatment

    … by two population-PK tools, MyPKFiT and WAPPS-Hemo, in a cohort of male patients with severe HA treated with octocog alfa. Both web tools were able to overcome assay discrepancy and produced similar FVIII half-life estimations. However, WAPPS-Hemo generated significantly longer …

    lund Repository record for Haemophilia A - In pursuit of optimised outcomes via personalised treatment (opens in a new tab) Download PDF for Haemophilia A - In pursuit of optimised outcomes via personalised treatment (opens in a new tab)

  6. Pharmacokinetic and economic implications when switching between hemophilia A treatments

    Hemophilia is a bleeding disorder in which the blood is unable to form clots, and is also classified as severe (defined as having an endogenous factor VIII [FVIII] concentration < 1 IU/dL, or 1%), moderate (1-5%) or mild (5-50%). Those with severe hemophilia may spontaneously bleed without physical …

    waterloo Repository record for Pharmacokinetic and economic implications when switching between hemophilia A treatments (opens in a new tab)